tetano
Editor, Senior Moderator
Vaccine
. 2022 Feb 16;S0264-410X(22)00173-6.
doi: 10.1016/j.vaccine.2022.02.037. Online ahead of print.
The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats
Bartlomiej Kalaska[SUP] 1 [/SUP], Joanna Miklosz[SUP] 2 [/SUP], Justyna Swieton[SUP] 2 [/SUP], Aleksandra Jakimczuk[SUP] 2 [/SUP], Dariusz Pawlak[SUP] 3 [/SUP], Andrzej Mogielnicki[SUP] 2 [/SUP]
Affiliations
Abstract
ChAdOx1 nCoV-19 adenoviral vector vaccine (ChAd) against coronavirus disease 2019 has been associated with vaccine-induced thrombosis and thrombocytopenia (VITT), especially in young women who have presented with unusual localized thrombosis after receiving the vaccine. The pathogenesis of VITT remains incompletely understood. We tried to provide new insights into mechanisms underlying this phenomenon in the model of arterial thrombosis electrically induced in the carotid artery of female rats. At 28 days post-vaccination, ChAd induced SARS-CoV-2-specific neutralizing antibody responses in all animals. The analysis of the blood vessel/thrombus area showed slight luminal narrowing of the carotid artery with extravasation of blood in vaccinated rats. These small changes were not accompanied by differences in thrombus weight and composition. The vaccinated animals presented a slight increase (by around 14-24%) in platelet aggregation. ChAd did not significantly affect blood coagulation, platelet counts, and their activation markers. Unaffected thrombus formation, the lack of thrombocytopenia and all the measured blood and hemostasis parameters that predominantly stayed unchanged, indicate that the ChAd does not increase the risk of arterial thrombosis development in female rats.
Keywords: Animals; Blood coagulation; Blood platelets; COVID-19; Thrombosis; Vaccines.
. 2022 Feb 16;S0264-410X(22)00173-6.
doi: 10.1016/j.vaccine.2022.02.037. Online ahead of print.
The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats
Bartlomiej Kalaska[SUP] 1 [/SUP], Joanna Miklosz[SUP] 2 [/SUP], Justyna Swieton[SUP] 2 [/SUP], Aleksandra Jakimczuk[SUP] 2 [/SUP], Dariusz Pawlak[SUP] 3 [/SUP], Andrzej Mogielnicki[SUP] 2 [/SUP]
Affiliations
- PMID: 35183388
- DOI: 10.1016/j.vaccine.2022.02.037
Abstract
ChAdOx1 nCoV-19 adenoviral vector vaccine (ChAd) against coronavirus disease 2019 has been associated with vaccine-induced thrombosis and thrombocytopenia (VITT), especially in young women who have presented with unusual localized thrombosis after receiving the vaccine. The pathogenesis of VITT remains incompletely understood. We tried to provide new insights into mechanisms underlying this phenomenon in the model of arterial thrombosis electrically induced in the carotid artery of female rats. At 28 days post-vaccination, ChAd induced SARS-CoV-2-specific neutralizing antibody responses in all animals. The analysis of the blood vessel/thrombus area showed slight luminal narrowing of the carotid artery with extravasation of blood in vaccinated rats. These small changes were not accompanied by differences in thrombus weight and composition. The vaccinated animals presented a slight increase (by around 14-24%) in platelet aggregation. ChAd did not significantly affect blood coagulation, platelet counts, and their activation markers. Unaffected thrombus formation, the lack of thrombocytopenia and all the measured blood and hemostasis parameters that predominantly stayed unchanged, indicate that the ChAd does not increase the risk of arterial thrombosis development in female rats.
Keywords: Animals; Blood coagulation; Blood platelets; COVID-19; Thrombosis; Vaccines.